Wells Fargo Initiates Coverage On Denali Therapeutics with Overweight Rating, Announces Price Target of $35

Benzinga · 2d ago
Wells Fargo analyst Benjamin Burnett initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Overweight rating and announces Price Target of $35.